Global Financing and Long-Term Technical Assistance for Multidrug-Resistant Tuberculosis: Scaling Up Access to Treatment

1. KeshavjeeS, FarmerPE (2010) Tuberculosis, drug resistance, and the history of modern medicine. N Engl J Med 367: 931–936.

2. World Health Organization (2009) Sixty-second World Health Assembly: Prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. WHO/WHA62.15/Agenda N. 12.9. Geneva: WHO.

3. KeshavjeeS, FarmerPE (2010) Time to put boots on the ground: making universal access to MDR-TB treatment a reality. Int J Tuberc Lung Dis 14: 1222–1225.

4. KeshavjeeS, FarmerPE (2010) Picking up the pace–scale-up of MDR tuberculosis treatment programs. N Engl J Med 363: 1781–1784.

5. World Health Organization (2013) Global tuberculosis report 2013. WHO/HTM/TB/2013.11. Geneva: WHO.

6. LongQ, SmithH, ZhangT, TangS, GarnerP (2011) Patient medical costs for tuberculosis treatment and impact on adherence in China: a systematic review. BMC Public Health 11: 393.

7. SuttonBS (2010) Evaluation of the public-private mix: how economics can contribute to tuberculosis control. Expert Rev Anti Infect Ther 8: 489–491.

8. MoonS, JambertE, ChildsM, von Schoen-AngererT (2011) A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries. Global Health 7: 39.

9. WaningB, KyleM, DiedrichsenE, SoucyL, HochstadtJ, et al. (2010) Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets. Global Health 6: 9.

10. GuptaR, CegielskiJP, EspinalMA, HenkensM, KimJY, et al. (2002) Increasing transparency in partnerships for health–introducing the Green Light Committee. Trop Med Int Health 7: 970–976.

11. Stop TB Partnership, World Health Organization. (2009) The Global Drug Facility: Comparative advantages. WHO/HTM/STB/2009.56. Geneva: WHO.

12. GuptaR, KimJY, EspinalMA, CaudronJM, PecoulB, et al. (2001) Responding to market failures in tuberculosis control. Science 293: 1049–1051.

13. Institute of Medicine (2012) Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis - Workshop Summary. Washington, D.C.: The National Academies Press.

14. Medecins sans Frontieres and the International Union Against Tuberculosis and Lung Disease (2012) DR-TB drugs under the microscope: Sources and prices for drug-resistant tuberculosis medicines. Geneva: WHO.

15. PooranA, PietersonE, DavidsM, TheronG, DhedaK (2013) What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS ONE 8: e54587.

16. HwangTJ, WaresDF, JafarovA, JakubowiakW, NunnP, et al. (2013) Safety of cycloserine and terizidone for the treatment of drug resistant tuberculosis: a meta-analysis. Int J Tuberc Lung Dis 17: 1257–1266.

17. NathansonE, GuptaR, HuamaniP, LeimaneV, PasechnikovAD, et al. (2004) Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 8: 1382–1384.

18. HwangTJ, DotsenkoS, JafarovA, WeyerK, FalzonD, et al. (2014) Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. BMJ Open 4: e004143.

19. Barder O, Kremer M, Levine R (2005) Making markets for vaccines: Ideas to action. Washington, D.C.: Center for Global Development.

20. GAVI Alliance Revised Co-financing Policy (2010) Geneva: GAVI Alliance. Available: http://www.gavialliance.org/library/gavi-documents/policies/gavi-alliance-revised-co-financing-policy. Accessed 20 August 2014.

21. SnyderCM, BegorW, BerndtER (2011) Economic perspectives on the advance market commitment for pneumococcal vaccines. Health Aff (Millwood) 30: 1508–1517.

22. BermanD, MalpaniR (2011) High time for GAVI to push for lower prices. Hum Vaccin 7: 290.

23. The Global Fund to Fight AIDS, Tuberculosis, and Malaria (2014) Grant Portfolio: Performance and Data. Available: http://portfolio.theglobalfund.org/en/Home/Index. Accessed 6 May 2014.

24. AtunR, WeilDE, EangMT, MwakyusaD (2010) Health-system strengthening and tuberculosis control. Lancet 375: 2169–2178.

25. MillerTL, McNabbSJ, HilsenrathP, PasipanodyaJ, WeisSE (2009) Personal and societal health quality lost to tuberculosis. PLoS ONE 4: e5080.

26. UNITAID (2014) MDR-TB Strategic Rotating Stockpile. Available: http://www.unitaid.eu/en/mdr-tb-strategic-rotating-stockpile. Accessed 15 June 2014.

27. MersonMH, CurranJW, GriffithCH, RagunanthanB (2012) The President's Emergency Plan for AIDS Relief: from successes of the emergency response to challenges of sustainable action. Health Aff (Millwood) 31: 1380–1388.

28. DiaconAH, PymA, GrobuschM, PatientiaR, RustomjeeR, et al. (2009) The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360: 2397–2405.

29. GlerMT, SkripconokaV, Sanchez-GaravitoE, XiaoH, Cabrera-RiveroJL, et al. (2012) Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 366: 2151–2160.

30. HwangTJ, CarpenterD, KesselheimAS (2014) Target small firms for antibiotic innovation. Science 344: 967–969.

31. LindorRA, AlloccoSJ, CheathamL, CorteseDA, HallRF, et al. (2013) Regulatory and reimbursement innovation. Sci Transl Med 5: 176cm3.

32. Institute of Medicine (2008) Partners in Health White Paper—Stemming the Tide of Multidrug-Resistant Tuberculosis: Major Barriers to Addressing the Growing Epidemic. Washington, D.C.: National Academies Press.